An analysis of 50 vendor websites found most said little about the limitations or potential harms of testing, prompting researchers to call for tighter oversight.
Many of the benefits claimed for health tests marketed directly to UK consumers are unsubstantiated, and most vendors provide little information about potential harms, according to an assessment published in BMJ Open.
The researchers reviewed the websites of 50 UK individuals, companies, and clinics, including major providers, that promote health tests to healthy people. They say the sector’s growth makes stronger consumer protection urgent. The global market is predicted to grow from $1.6 billion in 2023 to $3.2 billion by 2029.
The commercial tests include blood tests, medical imaging, physical examination, and physiological testing, sold individually or in packages. The researchers note there is scant evidence of their effectiveness in healthy people. They add that concerns have been raised about accuracy and the risk of false-positive and false-negative results, overdiagnosis, overtreatment, and mental or physical harm.
Tests Offered Outside NHS Recommendations
The sampled vendors offered blood tests such as full blood counts, liver function, and genetic testing. They also offered urine, stool, and saliva tests, including urinary protein, gut microbiome, and cortisol. Prices ranged from £6.99 for an at-home urine kidney albumin rapid test to £14,000 for a clinic-based “Platinum Assessment” that included multiple tests.
Many offerings did not align with National Health Service (NHS) advice and guidelines. Among the findings:
- Twelve vendors offered mammograms to normal-risk women younger than 50 without symptoms.
- Forty-five offered lipid and blood glucose tests to well adults younger than 40.
- Thirty-one offered follicle-stimulating hormone tests to all women older than 45.
- Twenty-eight offered tests for hidden blood in stool to adults younger than 50.
Thirteen organizations offered breast exams, nine offered pelvic exams, and 14 offered testicular exams to people without worrying symptoms. The researchers note that the NHS does not recommend these exams for people without symptoms.
Transparency about test content also varied. Some vendors described the tests in detail, while others listed only “vital blood checks” without specifying which ones. Some clinics stated that doctors “may recommend” additional tests after discussion on the day.
Benefit Claims Outpace Disclosure of Harms
Thirty-six of the 50 vendors claimed earlier diagnosis and better outcomes, and 48 claimed better knowledge of health. Sixteen claimed testing could help people live longer, despite no evidence of this, and 25 claimed reassurance.
By contrast, 70% of vendors did not explain the limitations or potential harms of testing, including those of intimate physical examinations. In all, 15 mentioned downsides in full or in part: nine mentioned overdiagnosis or false positives, eight mentioned underdiagnosis or false negatives, and nine mentioned inaccuracy.
Clinical oversight was also unevenly documented. The Care Quality Commission regulated 36 vendors, and doctors either owned or worked with 41. Nurses worked in 11 organizations, pharmacists in three, and a health care assistant in one. However, many websites offered little information on any of this. Despite some vendors including a report from a doctor, many still asked purchasers to involve their own NHS doctor.
The researchers also consulted a group of citizens convened for the study. Participants cited ease of access and hopes that a purchase would help their NHS interactions as reasons for considering commercial tests. They also said they needed help understanding results, which several clinics offered only for an additional fee.
Calls for Stronger Regulation
The researchers acknowledge limitations. The dynamic nature of internet searches may have missed some available tests, the search was limited to the UK, and not all information given to customers may have been available online.
“While it is possible that appropriate, high-quality health testing bought directly by consumers could fill gaps in NHS service delivery, it is also possible that poor-quality screening tests will negatively impact citizens through false positives (false alarms), false negatives (false reassurance) and loss of personal resources with little or no value gained by individuals,” the researchers write.
They add that NHS primary care is already experiencing the impact of following up on test results initiated by consumers rather than the NHS.
The authors contrast the oversight of health tests with that of drugs. “Compared with the sale of pharmaceutical products, there are far more safeguards around sales, advertising, promotion and regulation of providers. The regulation around sales of health tests to the public is far less developed, despite their capability of harm,” they write. “We suggest that gaps in regulation, particularly proactive approaches to health claims, should be urgently addressed.”
ID 210293847 © Microgen | Dreamstime.com